Nuvalent Inc., a clinical-stage biopharmaceutical company, has initiated its rolling New Drug Application (NDA) submission for zidesamtinib, a novel ROS1-selective inhibitor, for TKI pre-treated patients with advanced ROS1-positive non-small cell lung cancer (NSCLC). The U.S. Food and Drug Administration (FDA) has agreed to accept the NDA for participation in the Real-Time Oncology Review (RTOR) pilot program. This program allows for earlier submission of topline efficacy and safety results, potentially expediting the FDA's evaluation process. Completion of the NDA submission is targeted for the third quarter of 2025. Nuvalent continues to engage with the FDA on potential line-agnostic expansion opportunities, marking a significant step in advancing treatment options for patients with ROS1-positive NSCLC.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.